Companies /Healthcare

Bruker Corp

NASDAQ: BRKR Medical Devices
$60.91
▼ $0.68 (−1.10%) today
Markets open · 1:04pm ET

24/7 Wall St. View

BRKR at a Glance

Valuation
Market cap
$9.4B
Dividend yield
0.08%
Profitability
Revenue (TTM)
$3.5B
Profit margin
-3.5%
EPS (TTM)
$-1.10
Price
52-week range
$32 – $69
24/7 target
$73.39
Street target
$68.00
Earnings
Next report
Feb 10, 2027

Headquartered in Billerica, MA Fiscal year ends December NASDAQ: BRKR bruker.com

About Bruker

Bruker Corporation (Nasdaq: BRKR) develops and sells high-performance scientific instruments and analytical and diagnostic solutions. Its tools let scientists and engineers study life and materials at molecular, cellular and microscopic levels.

The company serves several markets:
- post-genomic life science research in molecular and cell biology
- specialty diagnostics
- applied and biopharma applications
- microscopy and nanoanalysis
- industrial and cleantech research
- next-generation semiconductor metrology supporting AI

Its product portfolio covers:
- preclinical imaging
- clinical phenomics research
- proteomics and multiomics
- spatial and single-cell biology
- functional, structural and condensate biology
- clinical microbiology and molecular diagnostics
- semiconductor industry solutions

Effective July 1, 2026, Bruker reorganized into four reportable segments. Three sit under the Bruker Scientific Instruments (BSI) umbrella: BSI Biosystems (BIOS), BSI Microbiology and Infection Diagnostics (BMID) and BSI NANO. The fourth is Bruker Energy & Supercon Technologies (BEST), which focuses on superconductor and energy technologies.

Revenue is diversified across Europe, the United States, Asia Pacific and other regions. Customers include academic and government research institutions, biopharma companies, clinical microbiology labs and industrial and semiconductor firms.

Bruker supplements organic growth with acquisitions. It has a Series A Mandatory Convertible Preferred Stock outstanding. Updated

Latest Activity

BRKRBruker
52-week high
$66.54
+2.76%vs prior 52-week high · Sep 30, 2026

Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.

Related stockstoday
  • AMEAMETEKCompetitor+4.2%
    Dec 31, 2025 · SEC 10-K
  • TMOThermo Fisher ScientificCompetitor+3.8%
    Dec 31, 2025 · SEC 10-K
  • AAgilent TechnologiesCompetitor+3.1%
    Dec 31, 2025 · SEC 10-K

Moves: Nov 9, 2026 · Alpha Vantage daily close

13 more related stocks · 3 have no US listing

Biggest movers · At the close
  • DUOLDuolingo$162.31+26.8%
  • OPENOpendoor Technologies$1.99+14.4%
  • BRKRBruker$63.73+12.8%
  • LYFTLyft$18.77+12.6%
  • MRNAModerna$255.26+11.7%
  • CIFRCipher Digital$6.46-20.5%
  • DDOGDatadog$188.37-14.6%
  • VRTVertiv$204.81-13.2%
  • CVSCVS Health$80.29-12.2%
  • PWRQuanta Services$577.78-12.1%

Duolingo closed up 26.8% at $162.31, the biggest move in a 383-stock priority universe that saw double-digit swings on both ends. Datadog, Vertiv, CVS and Quanta all gave up more than 12% in the same session.

BRKRBruker
Regular session
$60.03
-8.74%open $65.78

The selloff landed the same day Bruker filed its Q3 2026 earnings release, erasing roughly $800 million from a life science tools name. Moves this size are rare here, and the selling held into the close.

BRKRBruker
Q3 2026
EPS
$0.56
est $0.42+34.6%
Revenue
$874M
est $865M+1.0%

Cost discipline pushed non-GAAP operating margin up 400 basis points to 16.3%, beating expectations even as a goodwill impairment dragged GAAP results to a loss. Management reaffirmed full-year non-GAAP EPS guidance and pointed to double-digit EPS growth in FY27 behind a fifth straight quarter of book-to-bill above one.

Quarterly EPS — reported vs estimate
In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker's positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one.

Five straight quarters of orders outpacing shipments at the scientific instruments arm means the $8.6 billion lab-tools maker is building backlog while cost cuts do the heavy lifting on earnings. That combination is what investors in the group have been waiting to see.

We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.

The US academic market, the biggest overhang on lab tool makers all year, turned in the quarter, and Laukien is now underwriting double-digit EPS growth for FY27 off it. At an $8.6 billion market cap, that guidance is the whole thesis for Bruker.

BRKRBruker
New 52-week high$64.51+0.3% vs prior high · 2026-07-30

Bruker closed at $64.51, a fresh 52-week high that edges 0.26% past the July 30 peak and nearly doubles its March low near $32.71. The $9.8 billion name now has a clean new level for traders to defend.

Biggest movers · At the close
  • BRKRBruker$64.13+7.5%
  • TEMTempus AI$82.15+7.3%
  • IONQIonQ$45.01+5.8%
  • AFRMAffirm$71.54+5.1%
  • METAMeta$778.35+4.6%
  • ARMArm$304.35-8.5%
  • APPSDigital Turbine$10.94-5.2%
  • GPROGoPro$1.25-4.6%
  • GMGeneral Motors$80.22-4.2%
  • SNDKSanDisk$1,753.24-3.5%

Arm's 8.5% slide was the deepest move in a 111-stock priority list at Wednesday's close, with Bruker leading the upside at 7.5%.

BRKRBruker
Regular session
$64.88
+9.64%open $59.17

A 9.6% intraday jump adds close to a billion dollars of market value to a $9.9 billion company in a single session. Moves this size are rare for a life sciences tools name, so watch whether the gain holds into the close.

BRKRBruker
Dividend$0.05ex-date 2026-09-21 · 0.41% yield · 10 yrs paying

Bruker holds its nickel quarterly payout for a 10th straight year, unchanged from a year ago. At 0.41%, the yield is a token of consistency rather than income, so the instruments business is the reason to own it.

BRKR Coverage

Frequently Asked Questions

What does Bruker do?

Bruker Corporation (Nasdaq: BRKR) develops and sells high-performance scientific instruments and analytical and diagnostic solutions. Its tools let scientists and engineers study life and materials at molecular, cellular and microscopic levels.

What is the BRKR stock price target?

24/7 Wall St.'s 12-month price target for BRKR is $73.39, rated Buy. The Wall Street consensus target is $68.00. BRKR price prediction →